nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—ABCB1—kidney cancer	0.185	1	CbGaD
Trifluoperazine—XDH—Doxorubicin—kidney cancer	0.0771	0.193	CbGbCtD
Trifluoperazine—ABCB1—Temsirolimus—kidney cancer	0.0475	0.119	CbGbCtD
Trifluoperazine—HTR2C—Sorafenib—kidney cancer	0.0455	0.114	CbGbCtD
Trifluoperazine—CYP1A2—Pazopanib—kidney cancer	0.0285	0.0716	CbGbCtD
Trifluoperazine—ABCB1—Pazopanib—kidney cancer	0.025	0.0626	CbGbCtD
Trifluoperazine—ABCB1—Dactinomycin—kidney cancer	0.0228	0.0572	CbGbCtD
Trifluoperazine—CYP1A2—Erlotinib—kidney cancer	0.0204	0.0511	CbGbCtD
Trifluoperazine—ABCB1—Gemcitabine—kidney cancer	0.018	0.0452	CbGbCtD
Trifluoperazine—ABCB1—Erlotinib—kidney cancer	0.0178	0.0446	CbGbCtD
Trifluoperazine—CYP1A2—Sorafenib—kidney cancer	0.0166	0.0415	CbGbCtD
Trifluoperazine—ABCB1—Paclitaxel—kidney cancer	0.0163	0.0409	CbGbCtD
Trifluoperazine—ABCB1—Sorafenib—kidney cancer	0.0145	0.0363	CbGbCtD
Trifluoperazine—ABCB1—Vinblastine—kidney cancer	0.0143	0.0358	CbGbCtD
Trifluoperazine—ABCB1—Vincristine—kidney cancer	0.0141	0.0352	CbGbCtD
Trifluoperazine—ABCB1—Sunitinib—kidney cancer	0.0117	0.0294	CbGbCtD
Trifluoperazine—ABCB1—Doxorubicin—kidney cancer	0.00879	0.022	CbGbCtD
Trifluoperazine—S100A4—nephron tubule—kidney cancer	0.00385	0.0629	CbGeAlD
Trifluoperazine—S100A4—renal system—kidney cancer	0.0035	0.0572	CbGeAlD
Trifluoperazine—S100A4—kidney—kidney cancer	0.00339	0.0553	CbGeAlD
Trifluoperazine—S100A4—cortex of kidney—kidney cancer	0.0033	0.0538	CbGeAlD
Trifluoperazine—CYP1A2—urine—kidney cancer	0.0032	0.0522	CbGeAlD
Trifluoperazine—S100A4—cardiac atrium—kidney cancer	0.00314	0.0512	CbGeAlD
Trifluoperazine—UGT1A4—renal system—kidney cancer	0.00308	0.0502	CbGeAlD
Trifluoperazine—UGT1A4—kidney—kidney cancer	0.00297	0.0485	CbGeAlD
Trifluoperazine—TNNC1—cardiac atrium—kidney cancer	0.00264	0.0431	CbGeAlD
Trifluoperazine—HTR2A—urine—kidney cancer	0.0025	0.0408	CbGeAlD
Trifluoperazine—XDH—renal system—kidney cancer	0.00224	0.0366	CbGeAlD
Trifluoperazine—XDH—kidney—kidney cancer	0.00217	0.0354	CbGeAlD
Trifluoperazine—EBP—Sirolimus—Temsirolimus—kidney cancer	0.00167	0.306	CbGdCrCtD
Trifluoperazine—EBP—Sirolimus—Everolimus—kidney cancer	0.00167	0.306	CbGdCrCtD
Trifluoperazine—EBP—Temsirolimus—Everolimus—kidney cancer	0.00167	0.306	CbGdCrCtD
Trifluoperazine—CALM3—nephron tubule—kidney cancer	0.00141	0.0231	CbGeAlD
Trifluoperazine—SIGMAR1—nephron tubule—kidney cancer	0.00126	0.0206	CbGeAlD
Trifluoperazine—CALM3—cortex of kidney—kidney cancer	0.00121	0.0197	CbGeAlD
Trifluoperazine—CALM3—cardiac atrium—kidney cancer	0.00115	0.0188	CbGeAlD
Trifluoperazine—CALM2—nephron tubule—kidney cancer	0.00111	0.0181	CbGeAlD
Trifluoperazine—CALM1—nephron tubule—kidney cancer	0.0011	0.018	CbGeAlD
Trifluoperazine—SIGMAR1—cortex of kidney—kidney cancer	0.00108	0.0176	CbGeAlD
Trifluoperazine—SIGMAR1—cardiac atrium—kidney cancer	0.00103	0.0168	CbGeAlD
Trifluoperazine—HTR1A—renal system—kidney cancer	0.00103	0.0167	CbGeAlD
Trifluoperazine—CALM2—renal system—kidney cancer	0.00101	0.0165	CbGeAlD
Trifluoperazine—CALM1—renal system—kidney cancer	0.001	0.0164	CbGeAlD
Trifluoperazine—Antrafenine—PTGS1—kidney cancer	0.000984	0.236	CrCbGaD
Trifluoperazine—CALM2—kidney—kidney cancer	0.000975	0.0159	CbGeAlD
Trifluoperazine—CALM1—kidney—kidney cancer	0.00097	0.0158	CbGeAlD
Trifluoperazine—CALM2—cortex of kidney—kidney cancer	0.000949	0.0155	CbGeAlD
Trifluoperazine—ADRA1A—renal system—kidney cancer	0.000946	0.0154	CbGeAlD
Trifluoperazine—CALM1—cortex of kidney—kidney cancer	0.000945	0.0154	CbGeAlD
Trifluoperazine—CALM2—gonad—kidney cancer	0.000904	0.0148	CbGeAlD
Trifluoperazine—CALM2—cardiac atrium—kidney cancer	0.000903	0.0147	CbGeAlD
Trifluoperazine—CALM1—gonad—kidney cancer	0.0009	0.0147	CbGeAlD
Trifluoperazine—CALM1—cardiac atrium—kidney cancer	0.000899	0.0147	CbGeAlD
Trifluoperazine—CYP1A2—renal system—kidney cancer	0.000782	0.0128	CbGeAlD
Trifluoperazine—HTR2A—renal system—kidney cancer	0.000612	0.00998	CbGeAlD
Trifluoperazine—HTR2A—kidney—kidney cancer	0.000591	0.00965	CbGeAlD
Trifluoperazine—Antrafenine—PTGS2—kidney cancer	0.000562	0.135	CrCbGaD
Trifluoperazine—HTR2A—gonad—kidney cancer	0.000548	0.00895	CbGeAlD
Trifluoperazine—EBP—Azacitidine—Gemcitabine—kidney cancer	0.00045	0.0823	CbGdCrCtD
Trifluoperazine—ABCB1—nephron tubule—kidney cancer	0.000441	0.0072	CbGeAlD
Trifluoperazine—Ethopropazine—BCHE—kidney cancer	0.00043	0.103	CrCbGaD
Trifluoperazine—ABCB1—renal system—kidney cancer	0.000401	0.00654	CbGeAlD
Trifluoperazine—ABCB1—kidney—kidney cancer	0.000387	0.00632	CbGeAlD
Trifluoperazine—ABCB1—cortex of kidney—kidney cancer	0.000377	0.00616	CbGeAlD
Trifluoperazine—Dyspnoea—Everolimus—kidney cancer	0.000364	0.002	CcSEcCtD
Trifluoperazine—Urinary retention—Capecitabine—kidney cancer	0.000364	0.002	CcSEcCtD
Trifluoperazine—Cardiac arrest—Capecitabine—kidney cancer	0.000364	0.002	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Paclitaxel—kidney cancer	0.000364	0.002	CcSEcCtD
Trifluoperazine—Somnolence—Everolimus—kidney cancer	0.000363	0.00199	CcSEcCtD
Trifluoperazine—Dizziness—Temsirolimus—kidney cancer	0.000363	0.00199	CcSEcCtD
Trifluoperazine—Convulsion—Sunitinib—kidney cancer	0.000362	0.00199	CcSEcCtD
Trifluoperazine—Dry mouth—Sorafenib—kidney cancer	0.000362	0.00199	CcSEcCtD
Trifluoperazine—Dyskinesia—Doxorubicin—kidney cancer	0.000362	0.00199	CcSEcCtD
Trifluoperazine—Clomipramine—GSTP1—kidney cancer	0.000361	0.0866	CrCbGaD
Trifluoperazine—ABCB1—gonad—kidney cancer	0.000359	0.00587	CbGeAlD
Trifluoperazine—Insomnia—Erlotinib—kidney cancer	0.000357	0.00196	CcSEcCtD
Trifluoperazine—Decreased appetite—Vinblastine—kidney cancer	0.000356	0.00196	CcSEcCtD
Trifluoperazine—Decreased appetite—Everolimus—kidney cancer	0.000355	0.00195	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Sorafenib—kidney cancer	0.000355	0.00195	CcSEcCtD
Trifluoperazine—Leukopenia—Dactinomycin—kidney cancer	0.000354	0.00194	CcSEcCtD
Trifluoperazine—Fatigue—Everolimus—kidney cancer	0.000352	0.00193	CcSEcCtD
Trifluoperazine—Triflupromazine—BCHE—kidney cancer	0.000352	0.0845	CrCbGaD
Trifluoperazine—Dyspnoea—Erlotinib—kidney cancer	0.000351	0.00193	CcSEcCtD
Trifluoperazine—Constipation—Vinblastine—kidney cancer	0.000351	0.00193	CcSEcCtD
Trifluoperazine—Constipation—Everolimus—kidney cancer	0.000349	0.00192	CcSEcCtD
Trifluoperazine—Gait disturbance—Doxorubicin—kidney cancer	0.000348	0.00191	CcSEcCtD
Trifluoperazine—Dry mouth—Sunitinib—kidney cancer	0.000348	0.00191	CcSEcCtD
Trifluoperazine—Rash—Temsirolimus—kidney cancer	0.000346	0.0019	CcSEcCtD
Trifluoperazine—Dermatitis—Temsirolimus—kidney cancer	0.000346	0.0019	CcSEcCtD
Trifluoperazine—Skin disorder—Sorafenib—kidney cancer	0.000344	0.00189	CcSEcCtD
Trifluoperazine—Headache—Temsirolimus—kidney cancer	0.000344	0.00189	CcSEcCtD
Trifluoperazine—Decreased appetite—Erlotinib—kidney cancer	0.000343	0.00188	CcSEcCtD
Trifluoperazine—Dizziness—Pazopanib—kidney cancer	0.000342	0.00188	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Doxorubicin—kidney cancer	0.00034	0.00187	CcSEcCtD
Trifluoperazine—Fatigue—Erlotinib—kidney cancer	0.00034	0.00187	CcSEcCtD
Trifluoperazine—Anorexia—Sorafenib—kidney cancer	0.000338	0.00186	CcSEcCtD
Trifluoperazine—Muscular weakness—Capecitabine—kidney cancer	0.000338	0.00185	CcSEcCtD
Trifluoperazine—Constipation—Erlotinib—kidney cancer	0.000337	0.00185	CcSEcCtD
Trifluoperazine—Erythema—Gemcitabine—kidney cancer	0.000335	0.00184	CcSEcCtD
Trifluoperazine—Skin disorder—Sunitinib—kidney cancer	0.000331	0.00182	CcSEcCtD
Trifluoperazine—Dysphagia—Capecitabine—kidney cancer	0.000331	0.00182	CcSEcCtD
Trifluoperazine—Asthma—Capecitabine—kidney cancer	0.000331	0.00182	CcSEcCtD
Trifluoperazine—Rash—Pazopanib—kidney cancer	0.000326	0.00179	CcSEcCtD
Trifluoperazine—Nausea—Temsirolimus—kidney cancer	0.000326	0.00179	CcSEcCtD
Trifluoperazine—Dermatitis—Pazopanib—kidney cancer	0.000326	0.00179	CcSEcCtD
Trifluoperazine—Bronchospasm—Capecitabine—kidney cancer	0.000325	0.00179	CcSEcCtD
Trifluoperazine—Anorexia—Sunitinib—kidney cancer	0.000325	0.00179	CcSEcCtD
Trifluoperazine—Agitation—Vincristine—kidney cancer	0.000325	0.00178	CcSEcCtD
Trifluoperazine—Headache—Pazopanib—kidney cancer	0.000324	0.00178	CcSEcCtD
Trifluoperazine—Body temperature increased—Everolimus—kidney cancer	0.000323	0.00177	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Doxorubicin—kidney cancer	0.000319	0.00175	CcSEcCtD
Trifluoperazine—Oedema peripheral—Paclitaxel—kidney cancer	0.000318	0.00174	CcSEcCtD
Trifluoperazine—Leukopenia—Vincristine—kidney cancer	0.000317	0.00174	CcSEcCtD
Trifluoperazine—Dyspnoea—Sorafenib—kidney cancer	0.000316	0.00174	CcSEcCtD
Trifluoperazine—Pancytopenia—Capecitabine—kidney cancer	0.000314	0.00172	CcSEcCtD
Trifluoperazine—Body temperature increased—Erlotinib—kidney cancer	0.000312	0.00171	CcSEcCtD
Trifluoperazine—Insomnia—Sunitinib—kidney cancer	0.000309	0.00169	CcSEcCtD
Trifluoperazine—Decreased appetite—Sorafenib—kidney cancer	0.000308	0.00169	CcSEcCtD
Trifluoperazine—Anorexia—Dactinomycin—kidney cancer	0.000308	0.00169	CcSEcCtD
Trifluoperazine—Nausea—Pazopanib—kidney cancer	0.000307	0.00169	CcSEcCtD
Trifluoperazine—Convulsion—Vincristine—kidney cancer	0.000306	0.00168	CcSEcCtD
Trifluoperazine—Fatigue—Sorafenib—kidney cancer	0.000306	0.00168	CcSEcCtD
Trifluoperazine—Dyspnoea—Sunitinib—kidney cancer	0.000304	0.00167	CcSEcCtD
Trifluoperazine—Constipation—Sorafenib—kidney cancer	0.000303	0.00166	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vinblastine—kidney cancer	0.000302	0.00166	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Capecitabine—kidney cancer	0.000302	0.00166	CcSEcCtD
Trifluoperazine—Weight increased—Capecitabine—kidney cancer	0.000301	0.00165	CcSEcCtD
Trifluoperazine—Hypersensitivity—Everolimus—kidney cancer	0.000301	0.00165	CcSEcCtD
Trifluoperazine—Leukopenia—Gemcitabine—kidney cancer	0.0003	0.00165	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Capecitabine—kidney cancer	0.000298	0.00164	CcSEcCtD
Trifluoperazine—Decreased appetite—Sunitinib—kidney cancer	0.000297	0.00163	CcSEcCtD
Trifluoperazine—Asthenia—Vinblastine—kidney cancer	0.000294	0.00162	CcSEcCtD
Trifluoperazine—Fatigue—Sunitinib—kidney cancer	0.000294	0.00161	CcSEcCtD
Trifluoperazine—Asthenia—Everolimus—kidney cancer	0.000293	0.00161	CcSEcCtD
Trifluoperazine—Cough—Gemcitabine—kidney cancer	0.000293	0.00161	CcSEcCtD
Trifluoperazine—Constipation—Sunitinib—kidney cancer	0.000292	0.0016	CcSEcCtD
Trifluoperazine—Pruritus—Everolimus—kidney cancer	0.000289	0.00159	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Vincristine—kidney cancer	0.000289	0.00158	CcSEcCtD
Trifluoperazine—Jaundice—Capecitabine—kidney cancer	0.000287	0.00158	CcSEcCtD
Trifluoperazine—Asthenia—Erlotinib—kidney cancer	0.000283	0.00155	CcSEcCtD
Trifluoperazine—Urticaria—Sorafenib—kidney cancer	0.000282	0.00155	CcSEcCtD
Trifluoperazine—Photosensitivity—Doxorubicin—kidney cancer	0.000281	0.00154	CcSEcCtD
Trifluoperazine—Erythema—Paclitaxel—kidney cancer	0.000281	0.00154	CcSEcCtD
Trifluoperazine—Decreased appetite—Dactinomycin—kidney cancer	0.000281	0.00154	CcSEcCtD
Trifluoperazine—Body temperature increased—Sorafenib—kidney cancer	0.00028	0.00154	CcSEcCtD
Trifluoperazine—Pruritus—Erlotinib—kidney cancer	0.000279	0.00153	CcSEcCtD
Trifluoperazine—Fatigue—Dactinomycin—kidney cancer	0.000278	0.00153	CcSEcCtD
Trifluoperazine—Agranulocytosis—Capecitabine—kidney cancer	0.000275	0.00151	CcSEcCtD
Trifluoperazine—Anorexia—Vincristine—kidney cancer	0.000275	0.00151	CcSEcCtD
Trifluoperazine—Eczema—Doxorubicin—kidney cancer	0.000275	0.00151	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000274	0.0015	CcSEcCtD
Trifluoperazine—Nervousness—Paclitaxel—kidney cancer	0.000273	0.0015	CcSEcCtD
Trifluoperazine—Dizziness—Vinblastine—kidney cancer	0.000271	0.00149	CcSEcCtD
Trifluoperazine—Dizziness—Everolimus—kidney cancer	0.00027	0.00148	CcSEcCtD
Trifluoperazine—Muscle spasms—Paclitaxel—kidney cancer	0.00027	0.00148	CcSEcCtD
Trifluoperazine—Body temperature increased—Sunitinib—kidney cancer	0.00027	0.00148	CcSEcCtD
Trifluoperazine—Hypotension—Vincristine—kidney cancer	0.00027	0.00148	CcSEcCtD
Trifluoperazine—Skin disorder—Gemcitabine—kidney cancer	0.000266	0.00146	CcSEcCtD
Trifluoperazine—Vision blurred—Paclitaxel—kidney cancer	0.000265	0.00145	CcSEcCtD
Trifluoperazine—Tremor—Paclitaxel—kidney cancer	0.000263	0.00144	CcSEcCtD
Trifluoperazine—Increased appetite—Doxorubicin—kidney cancer	0.000263	0.00144	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000261	0.00144	CcSEcCtD
Trifluoperazine—Hypersensitivity—Sorafenib—kidney cancer	0.000261	0.00143	CcSEcCtD
Trifluoperazine—Insomnia—Vincristine—kidney cancer	0.000261	0.00143	CcSEcCtD
Trifluoperazine—Anorexia—Gemcitabine—kidney cancer	0.000261	0.00143	CcSEcCtD
Trifluoperazine—Oedema peripheral—Capecitabine—kidney cancer	0.000261	0.00143	CcSEcCtD
Trifluoperazine—Dizziness—Erlotinib—kidney cancer	0.000261	0.00143	CcSEcCtD
Trifluoperazine—Agitation—Paclitaxel—kidney cancer	0.000258	0.00142	CcSEcCtD
Trifluoperazine—Rash—Everolimus—kidney cancer	0.000258	0.00141	CcSEcCtD
Trifluoperazine—Dermatitis—Everolimus—kidney cancer	0.000257	0.00141	CcSEcCtD
Trifluoperazine—Headache—Vinblastine—kidney cancer	0.000257	0.00141	CcSEcCtD
Trifluoperazine—Angioedema—Paclitaxel—kidney cancer	0.000257	0.00141	CcSEcCtD
Trifluoperazine—Headache—Everolimus—kidney cancer	0.000256	0.0014	CcSEcCtD
Trifluoperazine—Hypotension—Gemcitabine—kidney cancer	0.000256	0.0014	CcSEcCtD
Trifluoperazine—Body temperature increased—Dactinomycin—kidney cancer	0.000255	0.0014	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000255	0.0014	CcSEcCtD
Trifluoperazine—Asthenia—Sorafenib—kidney cancer	0.000254	0.0014	CcSEcCtD
Trifluoperazine—Flupentixol—ABCB1—kidney cancer	0.000253	0.0608	CrCbGaD
Trifluoperazine—Hypoglycaemia—Doxorubicin—kidney cancer	0.000253	0.00139	CcSEcCtD
Trifluoperazine—Leukopenia—Paclitaxel—kidney cancer	0.000251	0.00138	CcSEcCtD
Trifluoperazine—Hypersensitivity—Sunitinib—kidney cancer	0.000251	0.00138	CcSEcCtD
Trifluoperazine—Decreased appetite—Vincristine—kidney cancer	0.000251	0.00138	CcSEcCtD
Trifluoperazine—Pruritus—Sorafenib—kidney cancer	0.000251	0.00138	CcSEcCtD
Trifluoperazine—Fatigue—Vincristine—kidney cancer	0.000249	0.00137	CcSEcCtD
Trifluoperazine—Rash—Erlotinib—kidney cancer	0.000249	0.00136	CcSEcCtD
Trifluoperazine—Dermatitis—Erlotinib—kidney cancer	0.000248	0.00136	CcSEcCtD
Trifluoperazine—Insomnia—Gemcitabine—kidney cancer	0.000248	0.00136	CcSEcCtD
Trifluoperazine—Headache—Erlotinib—kidney cancer	0.000247	0.00136	CcSEcCtD
Trifluoperazine—Constipation—Vincristine—kidney cancer	0.000247	0.00135	CcSEcCtD
Trifluoperazine—Cough—Paclitaxel—kidney cancer	0.000245	0.00135	CcSEcCtD
Trifluoperazine—Asthenia—Sunitinib—kidney cancer	0.000245	0.00134	CcSEcCtD
Trifluoperazine—Dyspnoea—Gemcitabine—kidney cancer	0.000244	0.00134	CcSEcCtD
Trifluoperazine—Nausea—Vinblastine—kidney cancer	0.000244	0.00134	CcSEcCtD
Trifluoperazine—Somnolence—Gemcitabine—kidney cancer	0.000243	0.00134	CcSEcCtD
Trifluoperazine—Convulsion—Paclitaxel—kidney cancer	0.000243	0.00134	CcSEcCtD
Trifluoperazine—Nausea—Everolimus—kidney cancer	0.000243	0.00133	CcSEcCtD
Trifluoperazine—Pruritus—Sunitinib—kidney cancer	0.000241	0.00133	CcSEcCtD
Trifluoperazine—Decreased appetite—Gemcitabine—kidney cancer	0.000238	0.00131	CcSEcCtD
Trifluoperazine—Hypersensitivity—Dactinomycin—kidney cancer	0.000238	0.00131	CcSEcCtD
Trifluoperazine—Fatigue—Gemcitabine—kidney cancer	0.000236	0.0013	CcSEcCtD
Trifluoperazine—Cardiac arrest—Doxorubicin—kidney cancer	0.000235	0.00129	CcSEcCtD
Trifluoperazine—Dizziness—Sorafenib—kidney cancer	0.000234	0.00129	CcSEcCtD
Trifluoperazine—Constipation—Gemcitabine—kidney cancer	0.000234	0.00129	CcSEcCtD
Trifluoperazine—Nausea—Erlotinib—kidney cancer	0.000234	0.00129	CcSEcCtD
Trifluoperazine—Dry mouth—Paclitaxel—kidney cancer	0.000234	0.00128	CcSEcCtD
Trifluoperazine—Asthenia—Dactinomycin—kidney cancer	0.000232	0.00127	CcSEcCtD
Trifluoperazine—Erythema—Capecitabine—kidney cancer	0.00023	0.00127	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000229	0.00126	CcSEcCtD
Trifluoperazine—Body temperature increased—Vincristine—kidney cancer	0.000228	0.00125	CcSEcCtD
Trifluoperazine—Dizziness—Sunitinib—kidney cancer	0.000226	0.00124	CcSEcCtD
Trifluoperazine—Rash—Sorafenib—kidney cancer	0.000224	0.00123	CcSEcCtD
Trifluoperazine—Dermatitis—Sorafenib—kidney cancer	0.000223	0.00123	CcSEcCtD
Trifluoperazine—Skin disorder—Paclitaxel—kidney cancer	0.000223	0.00122	CcSEcCtD
Trifluoperazine—Headache—Sorafenib—kidney cancer	0.000222	0.00122	CcSEcCtD
Trifluoperazine—Muscle spasms—Capecitabine—kidney cancer	0.000222	0.00122	CcSEcCtD
Trifluoperazine—Anorexia—Paclitaxel—kidney cancer	0.000219	0.0012	CcSEcCtD
Trifluoperazine—Muscular weakness—Doxorubicin—kidney cancer	0.000218	0.00119	CcSEcCtD
Trifluoperazine—Vision blurred—Capecitabine—kidney cancer	0.000217	0.00119	CcSEcCtD
Trifluoperazine—Body temperature increased—Gemcitabine—kidney cancer	0.000216	0.00119	CcSEcCtD
Trifluoperazine—Tremor—Capecitabine—kidney cancer	0.000216	0.00119	CcSEcCtD
Trifluoperazine—Rash—Sunitinib—kidney cancer	0.000215	0.00118	CcSEcCtD
Trifluoperazine—Dermatitis—Sunitinib—kidney cancer	0.000215	0.00118	CcSEcCtD
Trifluoperazine—Hypotension—Paclitaxel—kidney cancer	0.000214	0.00118	CcSEcCtD
Trifluoperazine—Headache—Sunitinib—kidney cancer	0.000214	0.00117	CcSEcCtD
Trifluoperazine—Asthma—Doxorubicin—kidney cancer	0.000213	0.00117	CcSEcCtD
Trifluoperazine—Dysphagia—Doxorubicin—kidney cancer	0.000213	0.00117	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vincristine—kidney cancer	0.000213	0.00117	CcSEcCtD
Trifluoperazine—Eosinophilia—Doxorubicin—kidney cancer	0.000211	0.00116	CcSEcCtD
Trifluoperazine—Nausea—Sorafenib—kidney cancer	0.000211	0.00116	CcSEcCtD
Trifluoperazine—Insomnia—Paclitaxel—kidney cancer	0.000207	0.00114	CcSEcCtD
Trifluoperazine—Asthenia—Vincristine—kidney cancer	0.000207	0.00114	CcSEcCtD
Trifluoperazine—Leukopenia—Capecitabine—kidney cancer	0.000206	0.00113	CcSEcCtD
Trifluoperazine—Dyspnoea—Paclitaxel—kidney cancer	0.000204	0.00112	CcSEcCtD
Trifluoperazine—Somnolence—Paclitaxel—kidney cancer	0.000204	0.00112	CcSEcCtD
Trifluoperazine—Rash—Dactinomycin—kidney cancer	0.000204	0.00112	CcSEcCtD
Trifluoperazine—Nausea—Sunitinib—kidney cancer	0.000203	0.00111	CcSEcCtD
Trifluoperazine—Pancytopenia—Doxorubicin—kidney cancer	0.000203	0.00111	CcSEcCtD
Trifluoperazine—Cough—Capecitabine—kidney cancer	0.000201	0.0011	CcSEcCtD
Trifluoperazine—Decreased appetite—Paclitaxel—kidney cancer	0.000199	0.00109	CcSEcCtD
Trifluoperazine—Fatigue—Paclitaxel—kidney cancer	0.000198	0.00108	CcSEcCtD
Trifluoperazine—Asthenia—Gemcitabine—kidney cancer	0.000196	0.00108	CcSEcCtD
Trifluoperazine—Constipation—Paclitaxel—kidney cancer	0.000196	0.00108	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000195	0.00107	CcSEcCtD
Trifluoperazine—Weight increased—Doxorubicin—kidney cancer	0.000194	0.00107	CcSEcCtD
Trifluoperazine—Pruritus—Gemcitabine—kidney cancer	0.000194	0.00106	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Doxorubicin—kidney cancer	0.000192	0.00106	CcSEcCtD
Trifluoperazine—Dry mouth—Capecitabine—kidney cancer	0.000192	0.00105	CcSEcCtD
Trifluoperazine—Nausea—Dactinomycin—kidney cancer	0.000192	0.00105	CcSEcCtD
Trifluoperazine—Dizziness—Vincristine—kidney cancer	0.000191	0.00105	CcSEcCtD
Trifluoperazine—Drowsiness—Doxorubicin—kidney cancer	0.00019	0.00104	CcSEcCtD
Trifluoperazine—Jaundice—Doxorubicin—kidney cancer	0.000185	0.00102	CcSEcCtD
Trifluoperazine—Skin disorder—Capecitabine—kidney cancer	0.000183	0.001	CcSEcCtD
Trifluoperazine—Urticaria—Paclitaxel—kidney cancer	0.000182	0.001	CcSEcCtD
Trifluoperazine—Rash—Vincristine—kidney cancer	0.000182	0.000999	CcSEcCtD
Trifluoperazine—Dermatitis—Vincristine—kidney cancer	0.000182	0.000998	CcSEcCtD
Trifluoperazine—Body temperature increased—Paclitaxel—kidney cancer	0.000181	0.000995	CcSEcCtD
Trifluoperazine—Headache—Vincristine—kidney cancer	0.000181	0.000993	CcSEcCtD
Trifluoperazine—Anorexia—Capecitabine—kidney cancer	0.000179	0.000984	CcSEcCtD
Trifluoperazine—Agranulocytosis—Doxorubicin—kidney cancer	0.000177	0.000974	CcSEcCtD
Trifluoperazine—Hypotension—Capecitabine—kidney cancer	0.000176	0.000965	CcSEcCtD
Trifluoperazine—Rash—Gemcitabine—kidney cancer	0.000173	0.000948	CcSEcCtD
Trifluoperazine—Dermatitis—Gemcitabine—kidney cancer	0.000172	0.000947	CcSEcCtD
Trifluoperazine—Headache—Gemcitabine—kidney cancer	0.000172	0.000942	CcSEcCtD
Trifluoperazine—Nausea—Vincristine—kidney cancer	0.000171	0.000941	CcSEcCtD
Trifluoperazine—Insomnia—Capecitabine—kidney cancer	0.00017	0.000934	CcSEcCtD
Trifluoperazine—Chlorpromazine—BCHE—kidney cancer	0.00017	0.0408	CrCbGaD
Trifluoperazine—Hypersensitivity—Paclitaxel—kidney cancer	0.000169	0.000927	CcSEcCtD
Trifluoperazine—Oedema peripheral—Doxorubicin—kidney cancer	0.000168	0.000923	CcSEcCtD
Trifluoperazine—Dyspnoea—Capecitabine—kidney cancer	0.000168	0.000921	CcSEcCtD
Trifluoperazine—Asthenia—Paclitaxel—kidney cancer	0.000164	0.000903	CcSEcCtD
Trifluoperazine—Decreased appetite—Capecitabine—kidney cancer	0.000164	0.000898	CcSEcCtD
Trifluoperazine—Nausea—Gemcitabine—kidney cancer	0.000163	0.000893	CcSEcCtD
Trifluoperazine—Fatigue—Capecitabine—kidney cancer	0.000162	0.00089	CcSEcCtD
Trifluoperazine—Pruritus—Paclitaxel—kidney cancer	0.000162	0.00089	CcSEcCtD
Trifluoperazine—Constipation—Capecitabine—kidney cancer	0.000161	0.000883	CcSEcCtD
Trifluoperazine—Dizziness—Paclitaxel—kidney cancer	0.000152	0.000832	CcSEcCtD
Trifluoperazine—Urticaria—Capecitabine—kidney cancer	0.000149	0.00082	CcSEcCtD
Trifluoperazine—Body temperature increased—Capecitabine—kidney cancer	0.000149	0.000816	CcSEcCtD
Trifluoperazine—Erythema—Doxorubicin—kidney cancer	0.000149	0.000816	CcSEcCtD
Trifluoperazine—Rash—Paclitaxel—kidney cancer	0.000145	0.000793	CcSEcCtD
Trifluoperazine—Dermatitis—Paclitaxel—kidney cancer	0.000144	0.000793	CcSEcCtD
Trifluoperazine—Nervousness—Doxorubicin—kidney cancer	0.000144	0.000792	CcSEcCtD
Trifluoperazine—Headache—Paclitaxel—kidney cancer	0.000144	0.000788	CcSEcCtD
Trifluoperazine—Muscle spasms—Doxorubicin—kidney cancer	0.000143	0.000784	CcSEcCtD
Trifluoperazine—Nefazodone—ABCB1—kidney cancer	0.000141	0.034	CrCbGaD
Trifluoperazine—Vision blurred—Doxorubicin—kidney cancer	0.00014	0.000769	CcSEcCtD
Trifluoperazine—Hypersensitivity—Capecitabine—kidney cancer	0.000139	0.000761	CcSEcCtD
Trifluoperazine—Triflupromazine—ABCB1—kidney cancer	0.000138	0.0331	CrCbGaD
Trifluoperazine—Agitation—Doxorubicin—kidney cancer	0.000137	0.00075	CcSEcCtD
Trifluoperazine—Nausea—Paclitaxel—kidney cancer	0.000136	0.000747	CcSEcCtD
Trifluoperazine—Asthenia—Capecitabine—kidney cancer	0.000135	0.000741	CcSEcCtD
Trifluoperazine—Pruritus—Capecitabine—kidney cancer	0.000133	0.000731	CcSEcCtD
Trifluoperazine—Clozapine—CYP1A1—kidney cancer	0.000133	0.032	CrCbGaD
Trifluoperazine—Leukopenia—Doxorubicin—kidney cancer	0.000133	0.00073	CcSEcCtD
Trifluoperazine—Trazodone—ABCB1—kidney cancer	0.000131	0.0314	CrCbGaD
Trifluoperazine—Cough—Doxorubicin—kidney cancer	0.00013	0.000712	CcSEcCtD
Trifluoperazine—Convulsion—Doxorubicin—kidney cancer	0.000129	0.000707	CcSEcCtD
Trifluoperazine—Dizziness—Capecitabine—kidney cancer	0.000124	0.000683	CcSEcCtD
Trifluoperazine—Dry mouth—Doxorubicin—kidney cancer	0.000124	0.000679	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000121	0.000666	CcSEcCtD
Trifluoperazine—Rash—Capecitabine—kidney cancer	0.000119	0.000651	CcSEcCtD
Trifluoperazine—Dermatitis—Capecitabine—kidney cancer	0.000118	0.000651	CcSEcCtD
Trifluoperazine—Headache—Capecitabine—kidney cancer	0.000118	0.000647	CcSEcCtD
Trifluoperazine—Skin disorder—Doxorubicin—kidney cancer	0.000118	0.000647	CcSEcCtD
Trifluoperazine—Anorexia—Doxorubicin—kidney cancer	0.000116	0.000635	CcSEcCtD
Trifluoperazine—Hypotension—Doxorubicin—kidney cancer	0.000113	0.000622	CcSEcCtD
Trifluoperazine—Nausea—Capecitabine—kidney cancer	0.000112	0.000613	CcSEcCtD
Trifluoperazine—Insomnia—Doxorubicin—kidney cancer	0.00011	0.000602	CcSEcCtD
Trifluoperazine—Dyspnoea—Doxorubicin—kidney cancer	0.000108	0.000593	CcSEcCtD
Trifluoperazine—Somnolence—Doxorubicin—kidney cancer	0.000108	0.000592	CcSEcCtD
Trifluoperazine—Fluphenazine—ABCB1—kidney cancer	0.000106	0.0255	CrCbGaD
Trifluoperazine—Decreased appetite—Doxorubicin—kidney cancer	0.000105	0.000579	CcSEcCtD
Trifluoperazine—Fatigue—Doxorubicin—kidney cancer	0.000105	0.000574	CcSEcCtD
Trifluoperazine—Constipation—Doxorubicin—kidney cancer	0.000104	0.000569	CcSEcCtD
Trifluoperazine—Clomipramine—ABCB1—kidney cancer	9.7e-05	0.0233	CrCbGaD
Trifluoperazine—Urticaria—Doxorubicin—kidney cancer	9.63e-05	0.000529	CcSEcCtD
Trifluoperazine—Body temperature increased—Doxorubicin—kidney cancer	9.59e-05	0.000526	CcSEcCtD
Trifluoperazine—Hypersensitivity—Doxorubicin—kidney cancer	8.93e-05	0.00049	CcSEcCtD
Trifluoperazine—Asthenia—Doxorubicin—kidney cancer	8.7e-05	0.000478	CcSEcCtD
Trifluoperazine—Promethazine—ABCB1—kidney cancer	8.59e-05	0.0206	CrCbGaD
Trifluoperazine—Pruritus—Doxorubicin—kidney cancer	8.58e-05	0.000471	CcSEcCtD
Trifluoperazine—Quetiapine—ABCB1—kidney cancer	8.22e-05	0.0197	CrCbGaD
Trifluoperazine—Dizziness—Doxorubicin—kidney cancer	8.02e-05	0.00044	CcSEcCtD
Trifluoperazine—Rash—Doxorubicin—kidney cancer	7.65e-05	0.00042	CcSEcCtD
Trifluoperazine—Dermatitis—Doxorubicin—kidney cancer	7.64e-05	0.000419	CcSEcCtD
Trifluoperazine—Headache—Doxorubicin—kidney cancer	7.6e-05	0.000417	CcSEcCtD
Trifluoperazine—Nausea—Doxorubicin—kidney cancer	7.2e-05	0.000395	CcSEcCtD
Trifluoperazine—Clozapine—ABCB1—kidney cancer	7.07e-05	0.017	CrCbGaD
Trifluoperazine—Chlorpromazine—ABCB1—kidney cancer	6.65e-05	0.016	CrCbGaD
Trifluoperazine—CALM3—Signaling Pathways—APC—kidney cancer	5.25e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KIT—kidney cancer	5.25e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	5.24e-06	3.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CDKN1B—kidney cancer	5.22e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CDKN1B—kidney cancer	5.22e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PTEN—kidney cancer	5.2e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PTEN—kidney cancer	5.2e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL2—kidney cancer	5.15e-06	3.16e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL2—kidney cancer	5.13e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GSTM1—kidney cancer	5.12e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CTNNB1—kidney cancer	5.09e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	5.08e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—APC—kidney cancer	5.08e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KIT—kidney cancer	5.08e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KIT—kidney cancer	5.08e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—APC—kidney cancer	5.08e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RAF1—kidney cancer	5.05e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—KRAS—kidney cancer	5.03e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—MAPK3—kidney cancer	5.03e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RELA—kidney cancer	5.02e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CCND1—kidney cancer	5.02e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—JUN—kidney cancer	5.01e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	5e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—POMC—kidney cancer	5e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CCND1—kidney cancer	5e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ERBB2—kidney cancer	4.99e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	4.99e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—JUN—kidney cancer	4.99e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	4.97e-06	3.05e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PTEN—kidney cancer	4.97e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RAF1—kidney cancer	4.96e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RAF1—kidney cancer	4.95e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	4.95e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RELA—kidney cancer	4.94e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—BRAF—kidney cancer	4.94e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RELA—kidney cancer	4.93e-06	3.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CTNNB1—kidney cancer	4.93e-06	3.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CTNNB1—kidney cancer	4.93e-06	3.02e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MTOR—kidney cancer	4.93e-06	3.02e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	4.91e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	4.91e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ERBB2—kidney cancer	4.9e-06	3e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	4.9e-06	3e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RAF1—kidney cancer	4.87e-06	2.99e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—MAPK3—kidney cancer	4.86e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—MAPK3—kidney cancer	4.86e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	4.86e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RELA—kidney cancer	4.85e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CYP1A1—kidney cancer	4.85e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PTEN—kidney cancer	4.85e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MTOR—kidney cancer	4.85e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RELA—kidney cancer	4.84e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MTOR—kidney cancer	4.84e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—POMC—kidney cancer	4.84e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—POMC—kidney cancer	4.84e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PTEN—kidney cancer	4.82e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	4.82e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	4.81e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PTEN—kidney cancer	4.8e-06	2.94e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PTEN—kidney cancer	4.8e-06	2.94e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—MAPK1—kidney cancer	4.79e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—BRAF—kidney cancer	4.77e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—BRAF—kidney cancer	4.77e-06	2.93e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTGS2—kidney cancer	4.77e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MTOR—kidney cancer	4.76e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	4.75e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—MAPK1—kidney cancer	4.63e-06	2.84e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—MAPK1—kidney cancer	4.63e-06	2.84e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	4.62e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	4.62e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTGS2—kidney cancer	4.61e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTGS2—kidney cancer	4.61e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—MAPK3—kidney cancer	4.6e-06	2.82e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	4.55e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	4.54e-06	2.78e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—POMC—kidney cancer	4.53e-06	2.78e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL2—kidney cancer	4.52e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—KRAS—kidney cancer	4.52e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TP53—kidney cancer	4.47e-06	2.74e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	4.47e-06	2.74e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	4.45e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL2—kidney cancer	4.45e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—MAPK3—kidney cancer	4.45e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—MAPK3—kidney cancer	4.45e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL2—kidney cancer	4.44e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCND1—kidney cancer	4.41e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—JUN—kidney cancer	4.4e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—VEGFA—kidney cancer	4.38e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—MAPK1—kidney cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—KRAS—kidney cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—KRAS—kidney cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL2—kidney cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	4.37e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL2—kidney cancer	4.36e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	4.36e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCND1—kidney cancer	4.34e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—JUN—kidney cancer	4.33e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCND1—kidney cancer	4.33e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—JUN—kidney cancer	4.32e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	4.3e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	4.29e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCND1—kidney cancer	4.26e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PTEN—kidney cancer	4.26e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—JUN—kidney cancer	4.25e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	4.25e-06	2.6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MAPK3—kidney cancer	4.24e-06	2.6e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—JUN—kidney cancer	4.24e-06	2.6e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—MAPK1—kidney cancer	4.23e-06	2.59e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—MAPK1—kidney cancer	4.23e-06	2.59e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	4.22e-06	2.59e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	4.21e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PTEN—kidney cancer	4.19e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PTEN—kidney cancer	4.18e-06	2.56e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTEN—kidney cancer	4.16e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—PIK3CA—kidney cancer	4.15e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MAPK3—kidney cancer	4.14e-06	2.54e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KRAS—kidney cancer	4.13e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—kidney cancer	4.13e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RAF1—kidney cancer	4.12e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.12e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PTEN—kidney cancer	4.11e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MAPK3—kidney cancer	4.1e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MAPK3—kidney cancer	4.1e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RELA—kidney cancer	4.1e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	4.1e-06	2.51e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ERBB2—kidney cancer	4.08e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MAPK1—kidney cancer	4.04e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—kidney cancer	4.03e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MTOR—kidney cancer	4.02e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTEN—kidney cancer	4.02e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTEN—kidney cancer	4.02e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—PIK3CA—kidney cancer	4.02e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—PIK3CA—kidney cancer	4.02e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—kidney cancer	4.01e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KRAS—kidney cancer	3.99e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KRAS—kidney cancer	3.99e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—kidney cancer	3.99e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—kidney cancer	3.99e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RAF1—kidney cancer	3.99e-06	2.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RAF1—kidney cancer	3.99e-06	2.44e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.99e-06	2.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RELA—kidney cancer	3.97e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RELA—kidney cancer	3.97e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ERBB2—kidney cancer	3.94e-06	2.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ERBB2—kidney cancer	3.94e-06	2.42e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MAPK1—kidney cancer	3.94e-06	2.42e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	3.92e-06	2.4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MAPK1—kidney cancer	3.9e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MAPK1—kidney cancer	3.9e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MTOR—kidney cancer	3.89e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MTOR—kidney cancer	3.89e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—kidney cancer	3.85e-06	2.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KRAS—kidney cancer	3.81e-06	2.34e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—PIK3CA—kidney cancer	3.79e-06	2.33e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	3.78e-06	2.32e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CDKN1B—kidney cancer	3.78e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—kidney cancer	3.78e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KRAS—kidney cancer	3.72e-06	2.28e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	3.71e-06	2.28e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	3.7e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KRAS—kidney cancer	3.7e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL2—kidney cancer	3.7e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KRAS—kidney cancer	3.69e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KRAS—kidney cancer	3.69e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PIK3CA—kidney cancer	3.67e-06	2.25e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PIK3CA—kidney cancer	3.67e-06	2.25e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CDKN1B—kidney cancer	3.65e-06	2.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CDKN1B—kidney cancer	3.65e-06	2.24e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MAPK3—kidney cancer	3.64e-06	2.23e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—POMC—kidney cancer	3.62e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—kidney cancer	3.61e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—kidney cancer	3.6e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—JUN—kidney cancer	3.59e-06	2.2e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	3.58e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL2—kidney cancer	3.57e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL2—kidney cancer	3.57e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MAPK3—kidney cancer	3.57e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CTNNB1—kidney cancer	3.57e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—kidney cancer	3.54e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	3.51e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	3.5e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PIK3CA—kidney cancer	3.5e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—kidney cancer	3.48e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—kidney cancer	3.48e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—kidney cancer	3.48e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—JUN—kidney cancer	3.48e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—JUN—kidney cancer	3.48e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PTEN—kidney cancer	3.48e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—kidney cancer	3.47e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MAPK1—kidney cancer	3.46e-06	2.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CTNNB1—kidney cancer	3.45e-06	2.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CTNNB1—kidney cancer	3.45e-06	2.12e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	3.42e-06	2.1e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—kidney cancer	3.42e-06	2.1e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—kidney cancer	3.41e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	3.41e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	3.4e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MAPK1—kidney cancer	3.4e-06	2.08e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PIK3CA—kidney cancer	3.39e-06	2.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PIK3CA—kidney cancer	3.39e-06	2.08e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PTEN—kidney cancer	3.36e-06	2.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PTEN—kidney cancer	3.36e-06	2.06e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	3.34e-06	2.05e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	3.33e-06	2.04e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—kidney cancer	3.31e-06	2.03e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—kidney cancer	3.29e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KRAS—kidney cancer	3.27e-06	2e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KRAS—kidney cancer	3.22e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KRAS—kidney cancer	3.21e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KRAS—kidney cancer	3.16e-06	1.94e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTEN—kidney cancer	3.15e-06	1.93e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	3.15e-06	1.93e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—kidney cancer	3.14e-06	1.93e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—kidney cancer	3.04e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—kidney cancer	3.04e-06	1.86e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	3e-06	1.84e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MAPK3—kidney cancer	2.97e-06	1.82e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	2.95e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.95e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PIK3CA—kidney cancer	2.93e-06	1.8e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—kidney cancer	2.91e-06	1.78e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	2.9e-06	1.78e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	2.89e-06	1.77e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—kidney cancer	2.89e-06	1.77e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—kidney cancer	2.88e-06	1.77e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MAPK3—kidney cancer	2.87e-06	1.76e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MAPK3—kidney cancer	2.87e-06	1.76e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—kidney cancer	2.86e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—kidney cancer	2.85e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PIK3CA—kidney cancer	2.84e-06	1.74e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PIK3CA—kidney cancer	2.84e-06	1.74e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MAPK1—kidney cancer	2.83e-06	1.73e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—kidney cancer	2.81e-06	1.72e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—kidney cancer	2.8e-06	1.72e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—kidney cancer	2.8e-06	1.71e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—kidney cancer	2.8e-06	1.71e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MAPK1—kidney cancer	2.73e-06	1.68e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MAPK1—kidney cancer	2.73e-06	1.68e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KRAS—kidney cancer	2.67e-06	1.64e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KRAS—kidney cancer	2.58e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KRAS—kidney cancer	2.58e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTEN—kidney cancer	2.52e-06	1.54e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CA—kidney cancer	2.45e-06	1.5e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—kidney cancer	2.37e-06	1.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CA—kidney cancer	2.37e-06	1.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CA—kidney cancer	2.37e-06	1.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—kidney cancer	2.3e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—kidney cancer	2.3e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CA—kidney cancer	2.22e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.77e-06	1.09e-05	CbGpPWpGaD
